Scienture (NASDAQ:SCNX) & CorMedix (NASDAQ:CRMD) Head to Head Comparison

Scienture (NASDAQ:SCNX – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 19.5% of Scienture shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Scienture and CorMedix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Scienture N/A -53.51% -42.47%
CorMedix 15.49% 27.12% 13.88%

Volatility and Risk

Scienture has a beta of 3.57, indicating that its stock price is 257% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Scienture and CorMedix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scienture 1 1 1 0 2.00
CorMedix 0 2 8 0 2.80

Scienture presently has a consensus price target of $6.00, suggesting a potential upside of 100.67%. CorMedix has a consensus price target of $15.22, suggesting a potential upside of 215.81%. Given CorMedix’s stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Scienture.

Earnings & Valuation

This table compares Scienture and CorMedix”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Scienture $430,000.00 12.24 -$41.51 million ($52.50) -0.06
CorMedix $311.71 million 1.21 $163.05 million $0.69 6.99

CorMedix has higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Summary

CorMedix beats Scienture on 10 of the 13 factors compared between the two stocks.

About Scienture

(Get Free Report)

Scienture is a specialty pharmaceutical company focused on developing and commercializing prescription treatments, particularly for central nervous system disorders. Its work includes advancing medicines and drug-delivery formulations intended to address patient needs in these areas. The company’s portfolio has included ZolpiMist, an FDA-approved zolpidem tartrate oral spray used to treat insomnia. Scienture has focused primarily on the U.S. pharmaceutical market.

About CorMedix

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.